
1. nanomedicine (lond). 2017 mar;12(6):673-682. doi: 10.2217/nnm-2016-0381. epub
2017 feb 21.

vaccine nanoparticles protection hiv infection.

aikins me(1)(2), bazzill j(2)(3), moon jj(1)(2)(3).

author information: 
(1)department biomedical engineering, university michigan, ann arbor, mi
48109, usa.
(2)biointerfaces institute, university michigan, ann arbor, mi 48109, usa.
(3)department pharmaceutical sciences, university michigan, ann arbor, mi
48109, usa.

the development successful vaccine hiv major global challenge. 
antiretroviral therapy standard treatment hiv-1 infection.
however, 46% eligible people received therapy 2015.
furthermore, suboptimal adherence poses additional obstacles. therefore, is
an urgent need hiv-1 vaccine. promising clinical trial date is
phase iii rv144, first time demonstrated feasibility of
vaccine-mediated immune protection hiv-1. nevertheless, 31% efficacy 
and limited durability underscore major hurdles. here, discuss recent progress
in hiv-1 vaccine development special emphasis nanovaccines, are
at forefront efforts develop successful hiv-1 vaccine.

doi: 10.2217/nnm-2016-0381 
pmcid: pmc5331416
pmid: 28244816  [indexed medline]

